nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2D6—breast cancer	0.215	1	CbGaD
Arformoterol—CYP2A6—Letrozole—breast cancer	0.144	0.301	CbGbCtD
Arformoterol—CYP2C9—Anastrozole—breast cancer	0.0441	0.0922	CbGbCtD
Arformoterol—CYP2A6—Tamoxifen—breast cancer	0.0429	0.0896	CbGbCtD
Arformoterol—CYP2C19—Lapatinib—breast cancer	0.0354	0.074	CbGbCtD
Arformoterol—CYP2C9—Idarubicin—breast cancer	0.0334	0.0699	CbGbCtD
Arformoterol—CYP2A6—Fluorouracil—breast cancer	0.0316	0.066	CbGbCtD
Arformoterol—CYP2D6—Idarubicin—breast cancer	0.0306	0.0639	CbGbCtD
Arformoterol—CYP2C9—Capecitabine—breast cancer	0.0183	0.0383	CbGbCtD
Arformoterol—CYP2C19—Tamoxifen—breast cancer	0.0177	0.0371	CbGbCtD
Arformoterol—CYP2D6—Vinorelbine—breast cancer	0.0149	0.0312	CbGbCtD
Arformoterol—CYP2C9—Tamoxifen—breast cancer	0.0147	0.0308	CbGbCtD
Arformoterol—CYP2D6—Tamoxifen—breast cancer	0.0135	0.0282	CbGbCtD
Arformoterol—CYP2C9—Paclitaxel—breast cancer	0.0115	0.024	CbGbCtD
Arformoterol—CYP2C9—Fluorouracil—breast cancer	0.0109	0.0227	CbGbCtD
Arformoterol—CYP2D6—Vinblastine—breast cancer	0.0092	0.0192	CbGbCtD
Arformoterol—CYP2D6—Doxorubicin—breast cancer	0.00566	0.0118	CbGbCtD
Arformoterol—Dobutamine—COMT—breast cancer	0.000901	0.531	CrCbGaD
Arformoterol—Formoterol—CYP2D6—breast cancer	0.000325	0.191	CrCbGaD
Arformoterol—Labetalol—CYP2D6—breast cancer	0.000237	0.14	CrCbGaD
Arformoterol—Isoprenaline—CYP1A1—breast cancer	0.000235	0.138	CrCbGaD
Arformoterol—Cardiac disorder—Methotrexate—breast cancer	5.26e-05	0.000228	CcSEcCtD
Arformoterol—Skin disorder—Capecitabine—breast cancer	5.25e-05	0.000227	CcSEcCtD
Arformoterol—Urinary tract disorder—Epirubicin—breast cancer	5.24e-05	0.000227	CcSEcCtD
Arformoterol—Urticaria—Paclitaxel—breast cancer	5.23e-05	0.000227	CcSEcCtD
Arformoterol—Oedema peripheral—Epirubicin—breast cancer	5.22e-05	0.000226	CcSEcCtD
Arformoterol—Hypotension—Docetaxel—breast cancer	5.22e-05	0.000226	CcSEcCtD
Arformoterol—Haematuria—Doxorubicin—breast cancer	5.21e-05	0.000226	CcSEcCtD
Arformoterol—Connective tissue disorder—Epirubicin—breast cancer	5.21e-05	0.000226	CcSEcCtD
Arformoterol—Abdominal pain—Paclitaxel—breast cancer	5.21e-05	0.000226	CcSEcCtD
Arformoterol—Body temperature increased—Paclitaxel—breast cancer	5.21e-05	0.000226	CcSEcCtD
Arformoterol—Urethral disorder—Epirubicin—breast cancer	5.2e-05	0.000225	CcSEcCtD
Arformoterol—Vomiting—Irinotecan—breast cancer	5.14e-05	0.000222	CcSEcCtD
Arformoterol—Vomiting—Mitoxantrone—breast cancer	5.14e-05	0.000222	CcSEcCtD
Arformoterol—Sinusitis—Doxorubicin—breast cancer	5.13e-05	0.000222	CcSEcCtD
Arformoterol—Immune system disorder—Methotrexate—breast cancer	5.12e-05	0.000222	CcSEcCtD
Arformoterol—Dizziness—Fluorouracil—breast cancer	5.12e-05	0.000222	CcSEcCtD
Arformoterol—Visual impairment—Epirubicin—breast cancer	5.11e-05	0.000221	CcSEcCtD
Arformoterol—Mediastinal disorder—Methotrexate—breast cancer	5.11e-05	0.000221	CcSEcCtD
Arformoterol—Rash—Mitoxantrone—breast cancer	5.09e-05	0.000221	CcSEcCtD
Arformoterol—Rash—Irinotecan—breast cancer	5.09e-05	0.000221	CcSEcCtD
Arformoterol—Dermatitis—Irinotecan—breast cancer	5.09e-05	0.00022	CcSEcCtD
Arformoterol—Dermatitis—Mitoxantrone—breast cancer	5.09e-05	0.00022	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Docetaxel—breast cancer	5.09e-05	0.00022	CcSEcCtD
Arformoterol—Headache—Mitoxantrone—breast cancer	5.06e-05	0.000219	CcSEcCtD
Arformoterol—Headache—Irinotecan—breast cancer	5.06e-05	0.000219	CcSEcCtD
Arformoterol—Hypotension—Capecitabine—breast cancer	5.05e-05	0.000219	CcSEcCtD
Arformoterol—Insomnia—Docetaxel—breast cancer	5.05e-05	0.000219	CcSEcCtD
Arformoterol—Vomiting—Gemcitabine—breast cancer	5e-05	0.000217	CcSEcCtD
Arformoterol—Dyspnoea—Docetaxel—breast cancer	4.98e-05	0.000216	CcSEcCtD
Arformoterol—Somnolence—Docetaxel—breast cancer	4.96e-05	0.000215	CcSEcCtD
Arformoterol—Mental disorder—Methotrexate—breast cancer	4.96e-05	0.000215	CcSEcCtD
Arformoterol—Rash—Gemcitabine—breast cancer	4.96e-05	0.000215	CcSEcCtD
Arformoterol—Dermatitis—Gemcitabine—breast cancer	4.96e-05	0.000215	CcSEcCtD
Arformoterol—Malnutrition—Methotrexate—breast cancer	4.93e-05	0.000214	CcSEcCtD
Arformoterol—Headache—Gemcitabine—breast cancer	4.93e-05	0.000213	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Capecitabine—breast cancer	4.93e-05	0.000213	CcSEcCtD
Arformoterol—Cardiac disorder—Epirubicin—breast cancer	4.92e-05	0.000213	CcSEcCtD
Arformoterol—Vomiting—Fluorouracil—breast cancer	4.92e-05	0.000213	CcSEcCtD
Arformoterol—Rhinitis—Doxorubicin—breast cancer	4.92e-05	0.000213	CcSEcCtD
Arformoterol—Dyspepsia—Docetaxel—breast cancer	4.92e-05	0.000213	CcSEcCtD
Arformoterol—Insomnia—Capecitabine—breast cancer	4.89e-05	0.000212	CcSEcCtD
Arformoterol—Rash—Fluorouracil—breast cancer	4.88e-05	0.000211	CcSEcCtD
Arformoterol—Dermatitis—Fluorouracil—breast cancer	4.87e-05	0.000211	CcSEcCtD
Arformoterol—Pharyngitis—Doxorubicin—breast cancer	4.87e-05	0.000211	CcSEcCtD
Arformoterol—Hypersensitivity—Paclitaxel—breast cancer	4.85e-05	0.00021	CcSEcCtD
Arformoterol—Headache—Fluorouracil—breast cancer	4.85e-05	0.00021	CcSEcCtD
Arformoterol—Urinary tract disorder—Doxorubicin—breast cancer	4.84e-05	0.00021	CcSEcCtD
Arformoterol—Oedema peripheral—Doxorubicin—breast cancer	4.83e-05	0.000209	CcSEcCtD
Arformoterol—Dysgeusia—Methotrexate—breast cancer	4.83e-05	0.000209	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Docetaxel—breast cancer	4.82e-05	0.000209	CcSEcCtD
Arformoterol—Connective tissue disorder—Doxorubicin—breast cancer	4.82e-05	0.000209	CcSEcCtD
Arformoterol—Dyspnoea—Capecitabine—breast cancer	4.82e-05	0.000209	CcSEcCtD
Arformoterol—Fatigue—Docetaxel—breast cancer	4.81e-05	0.000209	CcSEcCtD
Arformoterol—Urethral disorder—Doxorubicin—breast cancer	4.81e-05	0.000208	CcSEcCtD
Arformoterol—Nausea—Irinotecan—breast cancer	4.8e-05	0.000208	CcSEcCtD
Arformoterol—Nausea—Mitoxantrone—breast cancer	4.8e-05	0.000208	CcSEcCtD
Arformoterol—Immune system disorder—Epirubicin—breast cancer	4.79e-05	0.000207	CcSEcCtD
Arformoterol—Mediastinal disorder—Epirubicin—breast cancer	4.78e-05	0.000207	CcSEcCtD
Arformoterol—Constipation—Docetaxel—breast cancer	4.78e-05	0.000207	CcSEcCtD
Arformoterol—Pain—Docetaxel—breast cancer	4.78e-05	0.000207	CcSEcCtD
Arformoterol—Back pain—Methotrexate—breast cancer	4.77e-05	0.000207	CcSEcCtD
Arformoterol—Dyspepsia—Capecitabine—breast cancer	4.76e-05	0.000206	CcSEcCtD
Arformoterol—Arrhythmia—Epirubicin—breast cancer	4.74e-05	0.000205	CcSEcCtD
Arformoterol—Visual impairment—Doxorubicin—breast cancer	4.73e-05	0.000205	CcSEcCtD
Arformoterol—Asthenia—Paclitaxel—breast cancer	4.73e-05	0.000205	CcSEcCtD
Arformoterol—Nausea—Gemcitabine—breast cancer	4.67e-05	0.000202	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Capecitabine—breast cancer	4.67e-05	0.000202	CcSEcCtD
Arformoterol—Fatigue—Capecitabine—breast cancer	4.66e-05	0.000202	CcSEcCtD
Arformoterol—Pruritus—Paclitaxel—breast cancer	4.66e-05	0.000202	CcSEcCtD
Arformoterol—Mental disorder—Epirubicin—breast cancer	4.64e-05	0.000201	CcSEcCtD
Arformoterol—Pain—Capecitabine—breast cancer	4.62e-05	0.0002	CcSEcCtD
Arformoterol—Constipation—Capecitabine—breast cancer	4.62e-05	0.0002	CcSEcCtD
Arformoterol—Malnutrition—Epirubicin—breast cancer	4.62e-05	0.0002	CcSEcCtD
Arformoterol—Feeling abnormal—Docetaxel—breast cancer	4.6e-05	0.000199	CcSEcCtD
Arformoterol—Nausea—Fluorouracil—breast cancer	4.6e-05	0.000199	CcSEcCtD
Arformoterol—Ill-defined disorder—Methotrexate—breast cancer	4.58e-05	0.000198	CcSEcCtD
Arformoterol—Gastrointestinal pain—Docetaxel—breast cancer	4.57e-05	0.000198	CcSEcCtD
Arformoterol—Cardiac disorder—Doxorubicin—breast cancer	4.55e-05	0.000197	CcSEcCtD
Arformoterol—Tension—Epirubicin—breast cancer	4.53e-05	0.000196	CcSEcCtD
Arformoterol—Dysgeusia—Epirubicin—breast cancer	4.52e-05	0.000196	CcSEcCtD
Arformoterol—Diarrhoea—Paclitaxel—breast cancer	4.51e-05	0.000195	CcSEcCtD
Arformoterol—Nervousness—Epirubicin—breast cancer	4.48e-05	0.000194	CcSEcCtD
Arformoterol—Back pain—Epirubicin—breast cancer	4.46e-05	0.000193	CcSEcCtD
Arformoterol—Feeling abnormal—Capecitabine—breast cancer	4.46e-05	0.000193	CcSEcCtD
Arformoterol—Malaise—Methotrexate—breast cancer	4.45e-05	0.000193	CcSEcCtD
Arformoterol—Muscle spasms—Epirubicin—breast cancer	4.44e-05	0.000192	CcSEcCtD
Arformoterol—Immune system disorder—Doxorubicin—breast cancer	4.43e-05	0.000192	CcSEcCtD
Arformoterol—Gastrointestinal pain—Capecitabine—breast cancer	4.42e-05	0.000191	CcSEcCtD
Arformoterol—Mediastinal disorder—Doxorubicin—breast cancer	4.42e-05	0.000191	CcSEcCtD
Arformoterol—Abdominal pain—Docetaxel—breast cancer	4.41e-05	0.000191	CcSEcCtD
Arformoterol—Body temperature increased—Docetaxel—breast cancer	4.41e-05	0.000191	CcSEcCtD
Arformoterol—Arrhythmia—Doxorubicin—breast cancer	4.38e-05	0.00019	CcSEcCtD
Arformoterol—Dizziness—Paclitaxel—breast cancer	4.36e-05	0.000189	CcSEcCtD
Arformoterol—Cough—Methotrexate—breast cancer	4.3e-05	0.000186	CcSEcCtD
Arformoterol—Mental disorder—Doxorubicin—breast cancer	4.3e-05	0.000186	CcSEcCtD
Arformoterol—Urticaria—Capecitabine—breast cancer	4.3e-05	0.000186	CcSEcCtD
Arformoterol—Ill-defined disorder—Epirubicin—breast cancer	4.28e-05	0.000185	CcSEcCtD
Arformoterol—Abdominal pain—Capecitabine—breast cancer	4.27e-05	0.000185	CcSEcCtD
Arformoterol—Body temperature increased—Capecitabine—breast cancer	4.27e-05	0.000185	CcSEcCtD
Arformoterol—Malnutrition—Doxorubicin—breast cancer	4.27e-05	0.000185	CcSEcCtD
Arformoterol—Agitation—Epirubicin—breast cancer	4.24e-05	0.000184	CcSEcCtD
Arformoterol—Myalgia—Methotrexate—breast cancer	4.2e-05	0.000182	CcSEcCtD
Arformoterol—Chest pain—Methotrexate—breast cancer	4.2e-05	0.000182	CcSEcCtD
Arformoterol—Arthralgia—Methotrexate—breast cancer	4.2e-05	0.000182	CcSEcCtD
Arformoterol—Tension—Doxorubicin—breast cancer	4.19e-05	0.000181	CcSEcCtD
Arformoterol—Vomiting—Paclitaxel—breast cancer	4.19e-05	0.000181	CcSEcCtD
Arformoterol—Dysgeusia—Doxorubicin—breast cancer	4.18e-05	0.000181	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	4.17e-05	0.000181	CcSEcCtD
Arformoterol—Malaise—Epirubicin—breast cancer	4.16e-05	0.00018	CcSEcCtD
Arformoterol—Rash—Paclitaxel—breast cancer	4.15e-05	0.00018	CcSEcCtD
Arformoterol—Dermatitis—Paclitaxel—breast cancer	4.15e-05	0.00018	CcSEcCtD
Arformoterol—Discomfort—Methotrexate—breast cancer	4.15e-05	0.00018	CcSEcCtD
Arformoterol—Nervousness—Doxorubicin—breast cancer	4.15e-05	0.00018	CcSEcCtD
Arformoterol—Back pain—Doxorubicin—breast cancer	4.13e-05	0.000179	CcSEcCtD
Arformoterol—Headache—Paclitaxel—breast cancer	4.13e-05	0.000179	CcSEcCtD
Arformoterol—Hypersensitivity—Docetaxel—breast cancer	4.11e-05	0.000178	CcSEcCtD
Arformoterol—Muscle spasms—Doxorubicin—breast cancer	4.11e-05	0.000178	CcSEcCtD
Arformoterol—Palpitations—Epirubicin—breast cancer	4.08e-05	0.000177	CcSEcCtD
Arformoterol—Cough—Epirubicin—breast cancer	4.03e-05	0.000174	CcSEcCtD
Arformoterol—Anaphylactic shock—Methotrexate—breast cancer	4.02e-05	0.000174	CcSEcCtD
Arformoterol—Asthenia—Docetaxel—breast cancer	4.01e-05	0.000174	CcSEcCtD
Arformoterol—Infection—Methotrexate—breast cancer	4e-05	0.000173	CcSEcCtD
Arformoterol—Hypertension—Epirubicin—breast cancer	3.98e-05	0.000173	CcSEcCtD
Arformoterol—Hypersensitivity—Capecitabine—breast cancer	3.98e-05	0.000173	CcSEcCtD
Arformoterol—Ill-defined disorder—Doxorubicin—breast cancer	3.96e-05	0.000172	CcSEcCtD
Arformoterol—Pruritus—Docetaxel—breast cancer	3.95e-05	0.000171	CcSEcCtD
Arformoterol—Nervous system disorder—Methotrexate—breast cancer	3.95e-05	0.000171	CcSEcCtD
Arformoterol—Myalgia—Epirubicin—breast cancer	3.93e-05	0.00017	CcSEcCtD
Arformoterol—Arthralgia—Epirubicin—breast cancer	3.93e-05	0.00017	CcSEcCtD
Arformoterol—Chest pain—Epirubicin—breast cancer	3.93e-05	0.00017	CcSEcCtD
Arformoterol—Agitation—Doxorubicin—breast cancer	3.92e-05	0.00017	CcSEcCtD
Arformoterol—Anxiety—Epirubicin—breast cancer	3.92e-05	0.00017	CcSEcCtD
Arformoterol—Nausea—Paclitaxel—breast cancer	3.91e-05	0.000169	CcSEcCtD
Arformoterol—Skin disorder—Methotrexate—breast cancer	3.91e-05	0.000169	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	3.9e-05	0.000169	CcSEcCtD
Arformoterol—Discomfort—Epirubicin—breast cancer	3.88e-05	0.000168	CcSEcCtD
Arformoterol—Asthenia—Capecitabine—breast cancer	3.88e-05	0.000168	CcSEcCtD
Arformoterol—Malaise—Doxorubicin—breast cancer	3.85e-05	0.000167	CcSEcCtD
Arformoterol—Dry mouth—Epirubicin—breast cancer	3.84e-05	0.000166	CcSEcCtD
Arformoterol—Pruritus—Capecitabine—breast cancer	3.83e-05	0.000166	CcSEcCtD
Arformoterol—Diarrhoea—Docetaxel—breast cancer	3.82e-05	0.000165	CcSEcCtD
Arformoterol—Palpitations—Doxorubicin—breast cancer	3.77e-05	0.000163	CcSEcCtD
Arformoterol—Anaphylactic shock—Epirubicin—breast cancer	3.77e-05	0.000163	CcSEcCtD
Arformoterol—Oedema—Epirubicin—breast cancer	3.77e-05	0.000163	CcSEcCtD
Arformoterol—Hypotension—Methotrexate—breast cancer	3.76e-05	0.000163	CcSEcCtD
Arformoterol—Infection—Epirubicin—breast cancer	3.74e-05	0.000162	CcSEcCtD
Arformoterol—Cough—Doxorubicin—breast cancer	3.73e-05	0.000161	CcSEcCtD
Arformoterol—Diarrhoea—Capecitabine—breast cancer	3.7e-05	0.00016	CcSEcCtD
Arformoterol—Nervous system disorder—Epirubicin—breast cancer	3.69e-05	0.00016	CcSEcCtD
Arformoterol—Dizziness—Docetaxel—breast cancer	3.69e-05	0.00016	CcSEcCtD
Arformoterol—Hypertension—Doxorubicin—breast cancer	3.69e-05	0.00016	CcSEcCtD
Arformoterol—Tachycardia—Epirubicin—breast cancer	3.68e-05	0.000159	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Methotrexate—breast cancer	3.67e-05	0.000159	CcSEcCtD
Arformoterol—Skin disorder—Epirubicin—breast cancer	3.66e-05	0.000158	CcSEcCtD
Arformoterol—Insomnia—Methotrexate—breast cancer	3.64e-05	0.000158	CcSEcCtD
Arformoterol—Arthralgia—Doxorubicin—breast cancer	3.64e-05	0.000157	CcSEcCtD
Arformoterol—Chest pain—Doxorubicin—breast cancer	3.64e-05	0.000157	CcSEcCtD
Arformoterol—Myalgia—Doxorubicin—breast cancer	3.64e-05	0.000157	CcSEcCtD
Arformoterol—Anxiety—Doxorubicin—breast cancer	3.62e-05	0.000157	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	3.61e-05	0.000156	CcSEcCtD
Arformoterol—Discomfort—Doxorubicin—breast cancer	3.59e-05	0.000156	CcSEcCtD
Arformoterol—Dyspnoea—Methotrexate—breast cancer	3.59e-05	0.000155	CcSEcCtD
Arformoterol—Somnolence—Methotrexate—breast cancer	3.58e-05	0.000155	CcSEcCtD
Arformoterol—Dizziness—Capecitabine—breast cancer	3.58e-05	0.000155	CcSEcCtD
Arformoterol—Dry mouth—Doxorubicin—breast cancer	3.56e-05	0.000154	CcSEcCtD
Arformoterol—Vomiting—Docetaxel—breast cancer	3.55e-05	0.000154	CcSEcCtD
Arformoterol—Dyspepsia—Methotrexate—breast cancer	3.54e-05	0.000153	CcSEcCtD
Arformoterol—Rash—Docetaxel—breast cancer	3.52e-05	0.000152	CcSEcCtD
Arformoterol—Hypotension—Epirubicin—breast cancer	3.52e-05	0.000152	CcSEcCtD
Arformoterol—Dermatitis—Docetaxel—breast cancer	3.52e-05	0.000152	CcSEcCtD
Arformoterol—Headache—Docetaxel—breast cancer	3.5e-05	0.000152	CcSEcCtD
Arformoterol—Anaphylactic shock—Doxorubicin—breast cancer	3.49e-05	0.000151	CcSEcCtD
Arformoterol—Oedema—Doxorubicin—breast cancer	3.49e-05	0.000151	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Methotrexate—breast cancer	3.47e-05	0.00015	CcSEcCtD
Arformoterol—Fatigue—Methotrexate—breast cancer	3.47e-05	0.00015	CcSEcCtD
Arformoterol—Infection—Doxorubicin—breast cancer	3.46e-05	0.00015	CcSEcCtD
Arformoterol—Pain—Methotrexate—breast cancer	3.44e-05	0.000149	CcSEcCtD
Arformoterol—Vomiting—Capecitabine—breast cancer	3.44e-05	0.000149	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Epirubicin—breast cancer	3.43e-05	0.000149	CcSEcCtD
Arformoterol—Nervous system disorder—Doxorubicin—breast cancer	3.42e-05	0.000148	CcSEcCtD
Arformoterol—Rash—Capecitabine—breast cancer	3.41e-05	0.000148	CcSEcCtD
Arformoterol—Insomnia—Epirubicin—breast cancer	3.41e-05	0.000148	CcSEcCtD
Arformoterol—Dermatitis—Capecitabine—breast cancer	3.41e-05	0.000147	CcSEcCtD
Arformoterol—Tachycardia—Doxorubicin—breast cancer	3.4e-05	0.000147	CcSEcCtD
Arformoterol—Headache—Capecitabine—breast cancer	3.39e-05	0.000147	CcSEcCtD
Arformoterol—Skin disorder—Doxorubicin—breast cancer	3.39e-05	0.000147	CcSEcCtD
Arformoterol—Dyspnoea—Epirubicin—breast cancer	3.36e-05	0.000145	CcSEcCtD
Arformoterol—Somnolence—Epirubicin—breast cancer	3.35e-05	0.000145	CcSEcCtD
Arformoterol—Nausea—Docetaxel—breast cancer	3.32e-05	0.000144	CcSEcCtD
Arformoterol—Feeling abnormal—Methotrexate—breast cancer	3.32e-05	0.000144	CcSEcCtD
Arformoterol—Dyspepsia—Epirubicin—breast cancer	3.32e-05	0.000144	CcSEcCtD
Arformoterol—Gastrointestinal pain—Methotrexate—breast cancer	3.29e-05	0.000143	CcSEcCtD
Arformoterol—Hypotension—Doxorubicin—breast cancer	3.26e-05	0.000141	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Epirubicin—breast cancer	3.25e-05	0.000141	CcSEcCtD
Arformoterol—Fatigue—Epirubicin—breast cancer	3.25e-05	0.000141	CcSEcCtD
Arformoterol—Constipation—Epirubicin—breast cancer	3.22e-05	0.000139	CcSEcCtD
Arformoterol—Pain—Epirubicin—breast cancer	3.22e-05	0.000139	CcSEcCtD
Arformoterol—Nausea—Capecitabine—breast cancer	3.21e-05	0.000139	CcSEcCtD
Arformoterol—Urticaria—Methotrexate—breast cancer	3.2e-05	0.000138	CcSEcCtD
Arformoterol—Abdominal pain—Methotrexate—breast cancer	3.18e-05	0.000138	CcSEcCtD
Arformoterol—Body temperature increased—Methotrexate—breast cancer	3.18e-05	0.000138	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Doxorubicin—breast cancer	3.18e-05	0.000138	CcSEcCtD
Arformoterol—Insomnia—Doxorubicin—breast cancer	3.15e-05	0.000137	CcSEcCtD
Arformoterol—Dyspnoea—Doxorubicin—breast cancer	3.11e-05	0.000135	CcSEcCtD
Arformoterol—Feeling abnormal—Epirubicin—breast cancer	3.1e-05	0.000134	CcSEcCtD
Arformoterol—Somnolence—Doxorubicin—breast cancer	3.1e-05	0.000134	CcSEcCtD
Arformoterol—Gastrointestinal pain—Epirubicin—breast cancer	3.08e-05	0.000133	CcSEcCtD
Arformoterol—Dyspepsia—Doxorubicin—breast cancer	3.07e-05	0.000133	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Doxorubicin—breast cancer	3.01e-05	0.00013	CcSEcCtD
Arformoterol—Fatigue—Doxorubicin—breast cancer	3e-05	0.00013	CcSEcCtD
Arformoterol—Urticaria—Epirubicin—breast cancer	2.99e-05	0.00013	CcSEcCtD
Arformoterol—Constipation—Doxorubicin—breast cancer	2.98e-05	0.000129	CcSEcCtD
Arformoterol—Pain—Doxorubicin—breast cancer	2.98e-05	0.000129	CcSEcCtD
Arformoterol—Abdominal pain—Epirubicin—breast cancer	2.98e-05	0.000129	CcSEcCtD
Arformoterol—Body temperature increased—Epirubicin—breast cancer	2.98e-05	0.000129	CcSEcCtD
Arformoterol—Hypersensitivity—Methotrexate—breast cancer	2.97e-05	0.000128	CcSEcCtD
Arformoterol—Asthenia—Methotrexate—breast cancer	2.89e-05	0.000125	CcSEcCtD
Arformoterol—Feeling abnormal—Doxorubicin—breast cancer	2.87e-05	0.000124	CcSEcCtD
Arformoterol—Gastrointestinal pain—Doxorubicin—breast cancer	2.85e-05	0.000123	CcSEcCtD
Arformoterol—Pruritus—Methotrexate—breast cancer	2.85e-05	0.000123	CcSEcCtD
Arformoterol—Hypersensitivity—Epirubicin—breast cancer	2.78e-05	0.00012	CcSEcCtD
Arformoterol—Urticaria—Doxorubicin—breast cancer	2.77e-05	0.00012	CcSEcCtD
Arformoterol—Abdominal pain—Doxorubicin—breast cancer	2.76e-05	0.000119	CcSEcCtD
Arformoterol—Body temperature increased—Doxorubicin—breast cancer	2.76e-05	0.000119	CcSEcCtD
Arformoterol—Diarrhoea—Methotrexate—breast cancer	2.75e-05	0.000119	CcSEcCtD
Arformoterol—Asthenia—Epirubicin—breast cancer	2.7e-05	0.000117	CcSEcCtD
Arformoterol—Pruritus—Epirubicin—breast cancer	2.66e-05	0.000115	CcSEcCtD
Arformoterol—Dizziness—Methotrexate—breast cancer	2.66e-05	0.000115	CcSEcCtD
Arformoterol—Diarrhoea—Epirubicin—breast cancer	2.58e-05	0.000112	CcSEcCtD
Arformoterol—Hypersensitivity—Doxorubicin—breast cancer	2.57e-05	0.000111	CcSEcCtD
Arformoterol—Vomiting—Methotrexate—breast cancer	2.56e-05	0.000111	CcSEcCtD
Arformoterol—Rash—Methotrexate—breast cancer	2.54e-05	0.00011	CcSEcCtD
Arformoterol—Dermatitis—Methotrexate—breast cancer	2.54e-05	0.00011	CcSEcCtD
Arformoterol—Headache—Methotrexate—breast cancer	2.52e-05	0.000109	CcSEcCtD
Arformoterol—Asthenia—Doxorubicin—breast cancer	2.5e-05	0.000108	CcSEcCtD
Arformoterol—Dizziness—Epirubicin—breast cancer	2.49e-05	0.000108	CcSEcCtD
Arformoterol—Pruritus—Doxorubicin—breast cancer	2.47e-05	0.000107	CcSEcCtD
Arformoterol—Vomiting—Epirubicin—breast cancer	2.39e-05	0.000104	CcSEcCtD
Arformoterol—Nausea—Methotrexate—breast cancer	2.39e-05	0.000104	CcSEcCtD
Arformoterol—Diarrhoea—Doxorubicin—breast cancer	2.38e-05	0.000103	CcSEcCtD
Arformoterol—Rash—Epirubicin—breast cancer	2.37e-05	0.000103	CcSEcCtD
Arformoterol—Dermatitis—Epirubicin—breast cancer	2.37e-05	0.000103	CcSEcCtD
Arformoterol—Headache—Epirubicin—breast cancer	2.36e-05	0.000102	CcSEcCtD
Arformoterol—Dizziness—Doxorubicin—breast cancer	2.3e-05	9.98e-05	CcSEcCtD
Arformoterol—Nausea—Epirubicin—breast cancer	2.24e-05	9.69e-05	CcSEcCtD
Arformoterol—Vomiting—Doxorubicin—breast cancer	2.22e-05	9.6e-05	CcSEcCtD
Arformoterol—Rash—Doxorubicin—breast cancer	2.2e-05	9.52e-05	CcSEcCtD
Arformoterol—Dermatitis—Doxorubicin—breast cancer	2.2e-05	9.51e-05	CcSEcCtD
Arformoterol—Headache—Doxorubicin—breast cancer	2.18e-05	9.46e-05	CcSEcCtD
Arformoterol—Nausea—Doxorubicin—breast cancer	2.07e-05	8.97e-05	CcSEcCtD
Arformoterol—ADRB1—Signaling Pathways—TERT—breast cancer	7.21e-06	9.79e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—FASN—breast cancer	7.16e-06	9.72e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—BCHE—breast cancer	7.13e-06	9.68e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP17A1—breast cancer	7.12e-06	9.68e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—breast cancer	7.08e-06	9.62e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP17A1—breast cancer	7.06e-06	9.59e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TERT—breast cancer	7.05e-06	9.58e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ENO1—breast cancer	7.05e-06	9.58e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS1—breast cancer	7.05e-06	9.58e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC5A5—breast cancer	7.04e-06	9.56e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGFR1—breast cancer	7e-06	9.51e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ENO1—breast cancer	6.99e-06	9.5e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS1—breast cancer	6.99e-06	9.5e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CAV1—breast cancer	6.97e-06	9.46e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	6.96e-06	9.46e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HIF1A—breast cancer	6.89e-06	9.37e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	6.87e-06	9.34e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2D6—breast cancer	6.85e-06	9.31e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGFR1—breast cancer	6.85e-06	9.3e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NQO1—breast cancer	6.8e-06	9.24e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC2A1—breast cancer	6.8e-06	9.24e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOA2—breast cancer	6.79e-06	9.22e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HIF1A—breast cancer	6.74e-06	9.16e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—LEP—breast cancer	6.73e-06	9.14e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOA2—breast cancer	6.73e-06	9.14e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CAV1—breast cancer	6.67e-06	9.06e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	6.66e-06	9.04e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP3A4—breast cancer	6.63e-06	9.01e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	6.6e-06	8.96e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KDR—breast cancer	6.59e-06	8.96e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—LEP—breast cancer	6.58e-06	8.94e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—FASN—breast cancer	6.58e-06	8.94e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—BCHE—breast cancer	6.55e-06	8.9e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—FASN—breast cancer	6.52e-06	8.86e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CAV1—breast cancer	6.52e-06	8.86e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1B1—breast cancer	6.52e-06	8.85e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—BCHE—breast cancer	6.5e-06	8.83e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC5A5—breast cancer	6.47e-06	8.8e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KDR—breast cancer	6.45e-06	8.76e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ESR1—breast cancer	6.42e-06	8.73e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC5A5—breast cancer	6.42e-06	8.72e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HSP90AA1—breast cancer	6.39e-06	8.68e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FN1—breast cancer	6.35e-06	8.62e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CG—breast cancer	6.34e-06	8.62e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ESR1—breast cancer	6.28e-06	8.54e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NFKBIA—breast cancer	6.27e-06	8.52e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC2A1—breast cancer	6.25e-06	8.49e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NQO1—breast cancer	6.25e-06	8.49e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NCOA1—breast cancer	6.22e-06	8.45e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NOTCH1—breast cancer	6.21e-06	8.44e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FN1—breast cancer	6.21e-06	8.44e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NQO1—breast cancer	6.2e-06	8.42e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC2A1—breast cancer	6.2e-06	8.42e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NFKBIA—breast cancer	6.13e-06	8.34e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—STK11—breast cancer	6.13e-06	8.33e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP19A1—breast cancer	6.13e-06	8.33e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP3A4—breast cancer	6.1e-06	8.28e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NOTCH1—breast cancer	6.08e-06	8.25e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APC—breast cancer	6.07e-06	8.25e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CG—breast cancer	6.07e-06	8.25e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KIT—breast cancer	6.07e-06	8.25e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	6.07e-06	8.25e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP3A4—breast cancer	6.04e-06	8.21e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	6.01e-06	8.17e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGF—breast cancer	6e-06	8.16e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1B1—breast cancer	5.99e-06	8.14e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1B1—breast cancer	5.94e-06	8.07e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CG—breast cancer	5.94e-06	8.07e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KIT—breast cancer	5.94e-06	8.07e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APC—breast cancer	5.94e-06	8.07e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HSP90AA1—breast cancer	5.88e-06	7.99e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGF—breast cancer	5.87e-06	7.98e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HSP90AA1—breast cancer	5.83e-06	7.92e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK3—breast cancer	5.82e-06	7.9e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.75e-06	7.81e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOA1—breast cancer	5.72e-06	7.77e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BRAF—breast cancer	5.71e-06	7.76e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—COMT—breast cancer	5.7e-06	7.74e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK3—breast cancer	5.69e-06	7.73e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—breast cancer	5.67e-06	7.7e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOA1—breast cancer	5.67e-06	7.7e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—STK11—breast cancer	5.64e-06	7.66e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP19A1—breast cancer	5.64e-06	7.66e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HMOX1—breast cancer	5.59e-06	7.6e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—STK11—breast cancer	5.59e-06	7.59e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP19A1—breast cancer	5.59e-06	7.59e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BRAF—breast cancer	5.58e-06	7.59e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ITPR1—breast cancer	5.58e-06	7.58e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CD—breast cancer	5.58e-06	7.58e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF1—breast cancer	5.56e-06	7.56e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT2—breast cancer	5.56e-06	7.55e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EGFR—breast cancer	5.53e-06	7.52e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ALB—breast cancer	5.51e-06	7.48e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF1—breast cancer	5.44e-06	7.39e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT2—breast cancer	5.44e-06	7.39e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EGFR—breast cancer	5.41e-06	7.35e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ABCB1—breast cancer	5.37e-06	7.29e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CD—breast cancer	5.34e-06	7.25e-05	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CA—breast cancer	5.29e-06	7.19e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SERPINE1—breast cancer	5.28e-06	7.18e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TYMS—breast cancer	5.27e-06	7.16e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NOS3—breast cancer	5.27e-06	7.16e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.24e-06	7.13e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—COMT—breast cancer	5.24e-06	7.12e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KRAS—breast cancer	5.23e-06	7.1e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CD—breast cancer	5.22e-06	7.1e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—breast cancer	5.21e-06	7.09e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NCOR1—breast cancer	5.21e-06	7.08e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—breast cancer	5.21e-06	7.08e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PLA2G4A—breast cancer	5.21e-06	7.08e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—COMT—breast cancer	5.19e-06	7.06e-05	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	5.17e-06	7.03e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—breast cancer	5.17e-06	7.02e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SERPINE1—breast cancer	5.17e-06	7.02e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HMOX1—breast cancer	5.14e-06	6.99e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ITPR1—breast cancer	5.13e-06	6.97e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KRAS—breast cancer	5.11e-06	6.95e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HMOX1—breast cancer	5.1e-06	6.93e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ITPR1—breast cancer	5.09e-06	6.91e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NOS3—breast cancer	5.04e-06	6.85e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GPX1—breast cancer	4.99e-06	6.78e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A1—breast cancer	4.94e-06	6.71e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCB1—breast cancer	4.94e-06	6.71e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NOS3—breast cancer	4.93e-06	6.7e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ERCC2—breast cancer	4.9e-06	6.66e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCB1—breast cancer	4.89e-06	6.65e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CB—breast cancer	4.86e-06	6.61e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TYMS—breast cancer	4.85e-06	6.59e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—breast cancer	4.82e-06	6.55e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TYMS—breast cancer	4.81e-06	6.53e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CA—breast cancer	4.8e-06	6.53e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PLA2G4A—breast cancer	4.79e-06	6.51e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOR1—breast cancer	4.79e-06	6.51e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—breast cancer	4.79e-06	6.51e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MDM2—breast cancer	4.78e-06	6.5e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RAF1—breast cancer	4.77e-06	6.48e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOR1—breast cancer	4.75e-06	6.45e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PLA2G4A—breast cancer	4.75e-06	6.45e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—breast cancer	4.75e-06	6.45e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RELA—breast cancer	4.75e-06	6.45e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB2—breast cancer	4.72e-06	6.41e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	4.7e-06	6.38e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MDM2—breast cancer	4.68e-06	6.36e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RAF1—breast cancer	4.66e-06	6.34e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CB—breast cancer	4.65e-06	6.32e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MTOR—breast cancer	4.65e-06	6.32e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RELA—breast cancer	4.64e-06	6.31e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB2—breast cancer	4.61e-06	6.27e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—MTHFR—breast cancer	4.6e-06	6.26e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GPX1—breast cancer	4.59e-06	6.24e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MTOR—breast cancer	4.55e-06	6.19e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CB—breast cancer	4.55e-06	6.19e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GPX1—breast cancer	4.55e-06	6.18e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A1—breast cancer	4.54e-06	6.17e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ERCC2—breast cancer	4.51e-06	6.12e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A1—breast cancer	4.5e-06	6.12e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL8—breast cancer	4.47e-06	6.08e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ERCC2—breast cancer	4.47e-06	6.07e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HRAS—breast cancer	4.44e-06	6.04e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL8—breast cancer	4.37e-06	5.94e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1B—breast cancer	4.37e-06	5.93e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HRAS—breast cancer	4.35e-06	5.91e-05	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT1—breast cancer	4.32e-06	5.87e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CASP3—breast cancer	4.28e-06	5.82e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—breast cancer	4.27e-06	5.81e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1B—breast cancer	4.27e-06	5.8e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—breast cancer	4.25e-06	5.78e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CAV1—breast cancer	4.25e-06	5.77e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—MTHFR—breast cancer	4.23e-06	5.75e-05	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT1—breast cancer	4.23e-06	5.74e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTEN—breast cancer	4.2e-06	5.71e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—MTHFR—breast cancer	4.2e-06	5.7e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CASP3—breast cancer	4.19e-06	5.69e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—breast cancer	4.18e-06	5.68e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—breast cancer	4.17e-06	5.66e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—breast cancer	4.16e-06	5.65e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUN—breast cancer	4.16e-06	5.65e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CTNNB1—breast cancer	4.13e-06	5.61e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—breast cancer	4.08e-06	5.54e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUN—breast cancer	4.07e-06	5.53e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.06e-06	5.51e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—breast cancer	4.04e-06	5.5e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CTNNB1—breast cancer	4.04e-06	5.48e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1A—breast cancer	4.03e-06	5.48e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTEN—breast cancer	4.02e-06	5.46e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—breast cancer	3.96e-06	5.38e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1A—breast cancer	3.94e-06	5.36e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK8—breast cancer	3.93e-06	5.35e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTEN—breast cancer	3.93e-06	5.34e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT1—breast cancer	3.92e-06	5.33e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CAV1—breast cancer	3.91e-06	5.31e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CAV1—breast cancer	3.87e-06	5.26e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CG—breast cancer	3.87e-06	5.26e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK8—breast cancer	3.85e-06	5.23e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT1—breast cancer	3.84e-06	5.21e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SRC—breast cancer	3.73e-06	5.07e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.7e-06	5.03e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SRC—breast cancer	3.65e-06	4.96e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—breast cancer	3.63e-06	4.94e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT3—breast cancer	3.6e-06	4.89e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CG—breast cancer	3.56e-06	4.83e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—breast cancer	3.55e-06	4.83e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CG—breast cancer	3.53e-06	4.79e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT3—breast cancer	3.52e-06	4.78e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK3—breast cancer	3.44e-06	4.67e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CD—breast cancer	3.4e-06	4.62e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK3—breast cancer	3.36e-06	4.57e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALB—breast cancer	3.36e-06	4.56e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MYC—breast cancer	3.34e-06	4.54e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TGFB1—breast cancer	3.33e-06	4.53e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MYC—breast cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGFR—breast cancer	3.27e-06	4.44e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TGFB1—breast cancer	3.26e-06	4.43e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NOS3—breast cancer	3.21e-06	4.36e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGFR—breast cancer	3.2e-06	4.34e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CD—breast cancer	3.13e-06	4.25e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CD—breast cancer	3.1e-06	4.21e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KRAS—breast cancer	3.09e-06	4.2e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALB—breast cancer	3.09e-06	4.2e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALB—breast cancer	3.06e-06	4.16e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KRAS—breast cancer	3.02e-06	4.1e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CB—breast cancer	2.96e-06	4.03e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CA—breast cancer	2.96e-06	4.03e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NOS3—breast cancer	2.95e-06	4.01e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—breast cancer	2.94e-06	3.99e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NOS3—breast cancer	2.93e-06	3.98e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CA—breast cancer	2.84e-06	3.85e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	2.78e-06	3.77e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—breast cancer	2.74e-06	3.73e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CB—breast cancer	2.73e-06	3.7e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CB—breast cancer	2.7e-06	3.67e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—breast cancer	2.7e-06	3.67e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—breast cancer	2.68e-06	3.65e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—breast cancer	2.68e-06	3.64e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HRAS—breast cancer	2.62e-06	3.57e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HRAS—breast cancer	2.57e-06	3.49e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTEN—breast cancer	2.56e-06	3.48e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—breast cancer	2.51e-06	3.41e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—breast cancer	2.46e-06	3.34e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKT1—breast cancer	2.42e-06	3.29e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTEN—breast cancer	2.36e-06	3.2e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTEN—breast cancer	2.34e-06	3.17e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT1—breast cancer	2.32e-06	3.15e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT1—breast cancer	2.27e-06	3.08e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CA—breast cancer	1.81e-06	2.46e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CA—breast cancer	1.66e-06	2.26e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CA—breast cancer	1.65e-06	2.24e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKT1—breast cancer	1.48e-06	2.01e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKT1—breast cancer	1.36e-06	1.84e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKT1—breast cancer	1.35e-06	1.83e-05	CbGpPWpGaD
